# PDUFA dates September 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-09

> 129 FDA catalysts are dated in September 2025, including 11 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in September 2025?

PDUFA dates in September 2025: PYRUKYND® (pyrukynd, AGIO) on September 7, 2025; ORLADEYO® (berotralstat, BCRX) on September 12, 2025; JAKAFI (ruxolitinib, INCY) on September 19, 2025; SPINRAZA (nusinersen, BIIB) on September 22, 2025; ISEMBYLD (apitegromab, SRRK) on September 22, 2025; KEYTRUDA® (pembrolizumab, MRK) on September 23, 2025; and 5 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-09)

Source: Press release filed with the SEC (EX-99), accession 0001439222-25-000087, https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm (retrieved 2026-11-12). Last confirmed 2025-07-31. Cite: https://sec-api.dev/fda-calendar/2025-09#answer

## PDUFA dates in September 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| September 7, 2025 | AGIOS PHARMACEUTICALS, INC. | AGIO | PYRUKYND® (pyrukynd) | Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm) |
| September 12, 2025 | BIOCRYST PHARMACEUTICALS INC | BCRX | ORLADEYO® (berotralstat) |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184325003152/f8k_051425.htm) |
| September 19, 2025 | INCYTE CORP | INCY | JAKAFI (ruxolitinib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm) |
| September 22, 2025 | BIOGEN INC. | BIIB | SPINRAZA (nusinersen) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm) |
| September 22, 2025 | Scholar Rock Holding Corp | SRRK | ISEMBYLD (apitegromab) | Spinal Muscular Atrophy | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm) |
| September 23, 2025 | Merck & Co., Inc. | MRK | KEYTRUDA® (pembrolizumab) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm) |
| September 25, 2025 | OMEROS CORP | OMER | YARTEMLEA® (narsoplimab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm) |
| September 26, 2025 | Edgewise Therapeutics, Inc. | EWTX |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm) |
| September 26, 2025 | CYTOKINETICS INC | CYTK | MYQORZO® (aficamten) | oHCM | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm) |
| September 28, 2025 | Sanofi | SNY | tolebrutinib |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525077305/d942506dex991.htm) |
| September 30, 2025 | Fortress Biotech, Inc. | FBIO | ZYCUBO (CUTX-101) | Menkes disease | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm) |

## All catalysts in September 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 1, 2025 | [Part 1 blinded - al001 primary completion](https://sec-api.dev/pdufa/part-1-blinded-al001) | ALEC | Frontotemporal Dementia | withdrawn | "NCT04374136 (A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-01 (ACTUAL); Lead Sponsor Alector Inc.; Results First Posted 2026-09-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04374136)) |
| September 1, 2025 | [Latozinemab primary completion](https://sec-api.dev/pdufa/latozinemab) | ALEC | Neurodegenerative Diseases | withdrawn | "NCT06111014 (Continuation Study for Latozinemab): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-01 (ACTUAL); Lead Sponsor Alector Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111014)) |
| September 2, 2025 | [TRYNGOLZA (olezarsen) topline data readout](https://sec-api.dev/pdufa/olezarsen) | IONS |  | completed, positive | "On September 2, 2025, we announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with sHTG." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/ef20054942_8k.htm)) |
| September 2, 2025 | [Verekitug topline data readout](https://sec-api.dev/pdufa/verekitug) | UPB | CRSwNP | completed, positive | "WALTHAM, Mass. - September 2, 2025 - Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced positive top-line results from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000202262625000005/upb-ex99_1.htm)) |
| September 2, 2025 | [LINZESS® (linaclotide) primary completion](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation (FC); Chronic Idiopathic Constipation (CIC) | completed | "NCT05652205 (A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05652205)) |
| September 2, 2025 | [Salbutamol hfa-134a primary completion](https://sec-api.dev/pdufa/salbutamol-hfa-134a) | GSK | Asthma | completed | "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06261957)) |
| September 2, 2025 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06411899 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06411899)) |
| September 3, 2025 | [Favezelimab/pembrolizumab primary completion](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT05508867 (A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508867)) |
| September 3, 2025 | [Bf-200 ala and red light led lamp primary completion](https://sec-api.dev/pdufa/bf-200-ala-and-red-light-led-lamp) | BFRI | Actinic Keratoses | completed | "NCT05662202 (Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662202)) |
| September 3, 2025 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761262 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250903, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22)) |
| September 4, 2025 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000084914625000069/lfvnq42025earningsrelease.htm)) |
| September 4, 2025 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myositis | completed | "NCT05379634 (A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05379634)) |
| September 4, 2025 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | completed | "NCT05882357 (Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882357)) |
| September 5, 2025 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000155837025011885/ibio-20250905xex99d1.htm)) |
| September 5, 2025 | [KANJINTI® (trastuzumab) interim data readout](https://sec-api.dev/pdufa/trastuzumab) | BNTX | HER2-positive unresectable or metastatic breast cancer | completed, met | "MAINZ, Germany and SHANGHAI, China, September 05, 2025 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") today announced that the pivotal Phase 3 trial (NCT06265428) which DualityBio is conducting in China to evaluate trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of progression free survival at a pre-specified interim analysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000055/a99120250905_bnt323xdb-130.htm)) |
| September 5, 2025 | [Tukysa (tucatinib) primary completion](https://sec-api.dev/pdufa/tucatinib) | PFE | HER2 Positive Breast Cancer | completed | "NCT05132582 (A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-05 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132582)) |
| September 6, 2025 | [Eno lime primary completion](https://sec-api.dev/pdufa/eno-lime) | HLN | Indigestion Acid; Indigestion; Nausea | completed | "NCT07140341 (A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-06 (ACTUAL); Lead Sponsor HALEON." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07140341)) |
| September 7, 2025 | [PYRUKYND® (pyrukynd) PDUFA date](https://sec-api.dev/pdufa/pyrukynd) | AGIO | Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia | delayed | "•PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-073125xfyxex991earnin.htm)) |
| September 7, 2025 | [PYRUKYND® (pyrukynd) NDA/BLA acceptance](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | completed | "The FDA accepted the sNDA and granted a PDUFA goal date of September 7, 2025, which the FDA subsequently extended to December 7, 2025 following our submission of a proposed REMS to mitigate the risk of hepatocellular injury that was described in the original PYRUKYND® sNDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000116/agio-20250930.htm)) |
| September 8, 2025 | [Darovasertib interim data readout](https://sec-api.dev/pdufa/darovasertib) | IDYA |  | completed, positive | "On September 8, 2025, the Company presented positive interim data at their 10-Year Anniversary R&D Day from its ongoing Phase 2 OptimUM-09 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma ("UM")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1676725/000119312525197605/d38716d8k.htm)) |
| September 8, 2025 | [Claseprubart topline data readout](https://sec-api.dev/pdufa/claseprubart) | DNTH |  | completed, positive | "New York City and Waltham, Mass., September 8, 2025 - Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced positive top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody positive (AChR+) generalized Myasthenia Gravis (gMG)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)) |
| September 9, 2025 | [Gemzar (gemcitabine) FDA approval](https://sec-api.dev/pdufa/gemcitabine) | JNJ |  | completed, approved | "NDA219683 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250909, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product INLEXZO (GEMCITABINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219683%22)) |
| September 9, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06323161 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323161)) |
| September 10, 2025 | [Rezatapopt interim data readout](https://sec-api.dev/pdufa/rezatapopt) | PMVP | TP53 Y220C and KRAS wild-type advanced solid tumors | scheduled | "PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis data" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-ex99_1.htm)) |
| September 10, 2025 | [IGALMI® (dexmedetomidine) topline data readout](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed, positive | "On September 10, 2025, we further announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had sustained effects on agitation and consistent benefit with repeat dosing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| September 10, 2025 | [Corcept NDA/BLA acceptance](https://sec-api.dev/pdufa/corcept) | CORT | platinum-resistant ovarian cancer | completed | "On September 10, 2025, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259d8k.htm)) |
| September 10, 2025 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20250910, review_priority STANDARD; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| September 10, 2025 | [Brolucizumab 6mg primary completion](https://sec-api.dev/pdufa/brolucizumab) | NVS | Macular Polypoidal Choroidal Vasculopathy (PCV) | completed | "NCT05666804 (Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-10 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05666804)) |
| September 10, 2025 | [Cosentyx (secukinumab) primary completion](https://sec-api.dev/pdufa/secukinumab) | NVS | Polymyalgia Rheumatica | completed | "NCT05767034 (Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-10 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05767034)) |
| September 10, 2025 | [Koselugo (selumetinib sulfate) label expansion decision](https://sec-api.dev/pdufa/selumetinib) | AZN |  | completed, approved | "NDA213756 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250910, review_priority PRIORITY; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213756%22)) |
| September 10, 2025 | [Koselugo (selumetinib; selumetinib sulfate) FDA approval](https://sec-api.dev/pdufa/selumetinib-selumetinib) | AZN |  | completed, approved | "NDA219943 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250910, review_priority PRIORITY; sponsor_name ASTRAZENECA; product KOSELUGO (SELUMETINIB; SELUMETINIB SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219943%22)) |
| September 11, 2025 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "EX-99.1 enGene Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-ex99_1.htm)) |
| September 11, 2025 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | completed | "NCT05983770 (Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05983770)) |
| September 11, 2025 | [UGN-103 primary completion](https://sec-api.dev/pdufa/ugn-103) | URGN | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder | completed | "NCT06331299 (A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor UroGen Pharma Ltd.; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331299)) |
| September 12, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX |  | scheduled | "The FDA also granted priority review of the application, with a Prescription Drug User Fee Act ("PDUFA") target action date of September 12, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184325003152/f8k_051425.htm)) |
| September 14, 2025 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Asthma | completed | "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04718389)) |
| September 15, 2025 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - September 15, 2025 - Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000077185625000022/csbr8-k7312025ex991xq126.htm)) |
| September 15, 2025 | [Airsupra (albuterol sulfate; budesonide) label expansion decision](https://sec-api.dev/pdufa/albuterol-budesonide) | AZN |  | completed, approved | "NDA214070 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20250915, review_priority STANDARD; sponsor_name ASTRAZENECA; product AIRSUPRA (ALBUTEROL SULFATE; BUDESONIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214070%22)) |
| September 15, 2025 | [L-3721 FDA approval](https://sec-api.dev/pdufa/l-3721) | CRMD |  | completed, approved | "a.The creation of the role of Chief Manufacturing Officer on September 15, 2025, which role, among other things, (i) is held by someone with experience developing pharmaceutical products that received FDA approval, (ii) has primary responsibility for managing the Company's pharmaceutical development and testing procedures and policies and assisting the Board with its oversight duties regarding the Company's development; and (iii) will create, implement, and maintain a policy of generally accepted testing principles and standards." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-8xkxaugust72026xex992.htm)) |
| September 15, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Early Alzheimer´s Disease | completed | "NCT04777409 (A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04777409)) |
| September 15, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06109311 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109311)) |
| September 2025 | [BMB-101 primary completion](https://sec-api.dev/pdufa/bmb-101) | DRUG | Absence Epilepsy; Jeavons Syndrome; Dravet Syndrome | delayed | "NCT06401538 (BMB-101 in Absence Epilepsy and DEE): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-09-15 (ESTIMATED); Lead Sponsor Bright Minds Biosciences Pty Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06401538)) |
| September 16, 2025 | [Semagludtide primary completion](https://sec-api.dev/pdufa/semagludtide) | NVO | Early Alzheimer's Disease | completed | "NCT04777396 (A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04777396)) |
| September 16, 2025 | [Dtg/3tc primary completion](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV Infections | completed | "NCT05917509 (A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05917509)) |
| September 16, 2025 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Bronchiectasis | completed | "NCT06280391 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280391)) |
| September 16, 2025 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250916, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| September 17, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "CITY, Calif., September 17, 2025 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925090834/tm2526049d1_ex99-1.htm)) |
| September 17, 2025 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | completed | "NCT06042478 (Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042478)) |
| September 17, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | withdrawn | "NCT06237309 (REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06237309)) |
| September 18, 2025 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | completed, positive | "SAN DIEGO - September 18, 2025 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925029349/ex_860445.htm)) |
| September 18, 2025 | [Carotuximab interim data readout](https://sec-api.dev/pdufa/carotuximab) | KAPA |  | scheduled | "September 11, 2025, Kairos Pharma, Ltd., a Delaware corporation (the "Company"), issued a press release announcing that it will host a premier KOL event on Thursday, September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/form8-k.htm)) |
| September 18, 2025 | [BENDEKA (bendamustine) NDA/BLA submission](https://sec-api.dev/pdufa/bendamustine) | TEVA |  | completed | "Similarly, on September 18, 2025, Teva and Eagle filed suit against Almaject, Inc. and Alvogen, Inc. in the District of Delaware following the filing of another 505(b)(2) NDA for a generic BENDEKA product." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| September 18, 2025 | [Replimune Group, Inc. complete response letter (CRL)](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed, complete response letter | "On September 18, 2025 we announced that, following the type A meeting with the FDA to discuss the CRL, which was conducted on September 16, 2025, we were evaluating feedback received during the meeting to determine our next steps and that, at that time, a path forward under the accelerated approval pathway had not been determined." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm)) |
| September 18, 2025 | [AFX3772 primary completion](https://sec-api.dev/pdufa/afx3772) | GSK | Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal | completed | "NCT05412030 (A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-18 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05412030)) |
| September 18, 2025 | [Rsvt vaccine primary completion](https://sec-api.dev/pdufa/rsvt-vaccine) | SNY | RSV Immunization | withdrawn | "NCT06397768 (Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-18 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06397768)) |
| September 18, 2025 | [JAKAFI (ruxolitinib) label expansion decision](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA215309 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250918, review_priority STANDARD; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22)) |
| September 19, 2025 | [JAKAFI (ruxolitinib) PDUFA date](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "The Prescription Drug User Fee Act (PDUFA) action date was extended by three months to September 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm)) |
| September 19, 2025 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) FDA approval](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "Keytruda Qlex \| pembrolizumab and berahyaluronidase alfa-pmph \| 9/19/2025 \| To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| September 19, 2025 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20250919, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| September 19, 2025 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Thrombotic Microangiopathy | completed | "NCT04543591 (Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04543591)) |
| September 19, 2025 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | IgA Nephropathy | completed | "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578834)) |
| September 19, 2025 | [Bezuclastinib primary completion](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "NCT04996875 ((Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04996875)) |
| September 19, 2025 | [NNC0519-0130 primary completion](https://sec-api.dev/pdufa/nnc0519-0130) | NVO | Diabetes Mellitus, Type 2 | completed | "NCT06326047 (A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06326047)) |
| September 19, 2025 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | completed | "NCT06586112 (A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06586112)) |
| September 20, 2025 | [20-valent pneumococcal conjugate vaccine primary completion](https://sec-api.dev/pdufa/20-valent-pneumococcal-conjugate-vaccine) | PFE | Pneumococcal Disease | completed | "NCT05512819 (A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-20 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05512819)) |
| September 22, 2025 | [SPINRAZA (nusinersen) PDUFA date](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, complete response letter | "•Nusinersen (SPINRAZA) higher dose regimen for SMA filings accepted by FDA and EMA; FDA PDUFA of September 22, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm)) |
| September 22, 2025 | [ZANVASTRO™ (zilganersen) topline data readout](https://sec-api.dev/pdufa/zilganersen) | IONS |  | completed, positive | "On September 22, 2025, we announced positive topline results from the pivotal study of zilganersen in children and adults living with AxD, a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036125035634/ef20055880_8k.htm)) |
| September 22, 2025 | [Eftilagimod alfa trial start](https://sec-api.dev/pdufa/eftilagimod-alfa) | IMMP | early-stage HR+/HER2-negative breast cancer | completed | "September 22, 2025 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the initiation of an investigator-initiated Phase II trial evaluating neoadjuvant eftilagimod alfa (efti) administered subcutaneously as monotherapy and then in combination with standard-of-care chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312525211928/d76406dex991.htm)) |
| September 22, 2025 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy | completed, complete response letter | "Exhibit 99.1 target action date for apitegromab of September 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm)) |
| September 22, 2025 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "HAYWARD, Calif., September 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full year ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/bntc-ex99_1.htm)) |
| September 22, 2025 | [Isembyld (apitegromab-mstn) complete response letter (CRL)](https://sec-api.dev/pdufa/apitegromab-mstn) | SRRK |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve tl action be! his application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761463_20250922.pdf%22)) |
| September 22, 2025 | [Ozuriftamab vedotin primary completion](https://sec-api.dev/pdufa/ozuriftamab-vedotin) | BCAB |  | completed | "NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-22 (ACTUAL); Lead Sponsor BioAtla, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05271604)) |
| September 22, 2025 | [Aro-apoc3 primary completion](https://sec-api.dev/pdufa/aro-apoc3) | ARWR | Dyslipidemias | completed | "NCT05413135 (Study of ARO-APOC3 in Adults With Dyslipidemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-22 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05413135)) |
| September 22, 2025 | [ABBV-382 primary completion](https://sec-api.dev/pdufa/abbv-382) | ABBV | Human Immuno-deficiency Virus (HIV) Disease | withdrawn | "NCT06032546 (A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-22 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-11-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06032546)) |
| September 22, 2025 | [SPINRAZA (nusinersen) complete response letter (CRL)](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA209531_20250922.pdf%22)) |
| September 23, 2025 | [ISEMBYLD (apitegromab) complete response letter (CRL)](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, complete response letter | "On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_8k.htm)) |
| September 23, 2025 | [KEYTRUDA® (pembrolizumab) PDUFA date](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | scheduled | "- 41 - approved solid tumor indications for Keytruda and set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 23, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm)) |
| September 23, 2025 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (September 23, 2025) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/ex_863501.htm)) |
| September 23, 2025 | [EXXUA (exxua) earnings report](https://sec-api.dev/pdufa/exxua) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA™" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774925029721/ex_818415.htm)) |
| September 23, 2025 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Acute Myeloid Leukemia (AML); Cancer | withdrawn | "NCT04161885 (A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04161885)) |
| September 23, 2025 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Non-alcoholic Fatty Liver Disease | completed | "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104319)) |
| September 23, 2025 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | completed | "NCT06588738 (A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588738)) |
| September 24, 2025 | [Ifezuntirgene inilparvovec topline data readout](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed, positive | "On September 24, 2025, the Company announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924x8k.htm)) |
| September 24, 2025 | [PepGen Inc. interim data readout](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed, positive | "On September 24, 2025, we reported positive initial clinical data, including a dose-dependent mean splicing correction (53.7%) at the 15 mg/kg dose level of the ongoing FREEDOM Phase 1, single ascending dose (SAD) study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1835597/000119312525276001/pepg-20250930.htm)) |
| September 24, 2025 | [PepGen Inc. interim data readout](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed, positive | "On September 24, 2025, we reported positive initial clinical data for the 15 mg/kg dose level of the FREEDOM study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091536/pepg-20251231.htm)) |
| September 24, 2025 | [Soticlestat primary completion](https://sec-api.dev/pdufa/soticlestat) | TAK | Dravet Syndrome (DS); Lennox Gastaut Syndrome (LGS) | withdrawn | "NCT05163314 (A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05163314)) |
| September 24, 2025 | [Fordadistrogene movaparvovec primary completion](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) | PFE | Duchenne Muscular Dystrophy | withdrawn | "NCT05689164 (A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05689164)) |
| September 24, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease; Type 2 Diabetes; Obesity | completed | "NCT06131372 (A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06131372)) |
| September 24, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Alopecia Areata | withdrawn | "NCT06444451 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06444451)) |
| September 25, 2025 | [YARTEMLEA® (narsoplimab) PDUFA date](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | scheduled | "Pursuant to the Prescription Drug User Fee Act ("PDUFA"), the class 2 resubmission was assigned September 25, 2025 as the target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| September 25, 2025 | [Selonabant trial start](https://sec-api.dev/pdufa/selonabant) | ANEB |  | completed | "On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/ex99-1.htm)) |
| September 25, 2025 | [Evkeeza (evinacumab-dgnb) label expansion decision](https://sec-api.dev/pdufa/evinacumab-dgnb) | REGN |  | completed, approved | "BLA761181 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250925, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EVKEEZA (EVINACUMAB-DGNB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761181%22)) |
| September 25, 2025 | [Inluriyo™ (imlunestrant) FDA approval](https://sec-api.dev/pdufa/imlunestrant) | LLY |  | completed, approved | "Inluriyo \| imlunestrant \| 9/25/2025 \| To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| September 25, 2025 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Dermatitis | completed | "NCT06280716 (A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280716)) |
| September 25, 2025 | [MRNA-1083 primary completion](https://sec-api.dev/pdufa/mrna-1083) | MRNA | Influenza; SARS-CoV-2 | completed | "NCT06508320 (A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508320)) |
| September 26, 2025 | [MYQORZO® (aficamten) NDA/BLA acceptance](https://sec-api.dev/pdufa/aficamten) | CYTK |  | completed | "For example, the FDA recently accepted and filed our NDA for aficamten for the treatment of oHCM and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025, which was subsequently extended to December 26, 2025 as a result of FDA considering our submission of a proposed REMS to be a major amendment to the NDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm)) |
| September 26, 2025 | [Edgewise Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | scheduled | "In December 2024, the FDA accepted the aficamtin New Drug Application (NDA) with a Prescription Drug User Fee Act (PDUFA) target action date set for September 26, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm)) |
| September 26, 2025 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | oHCM | delayed | "We have submitted an NDA to FDA for aficamten for the treatment of oHCM, which was accepted for filing with a PDUFA target action date of September 26, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm)) |
| September 26, 2025 | [ANKTIVA (inbakicept) FDA approval](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | completed, approved | "After SRS's motion for leave to amend was denied, on September 26, 2025, SRS sent the company a further notice of claims and essentially the same arbitration demand, asserting that the company had breached its obligations to exercise commercially reasonable efforts to achieve FDA approval of ANKTIVA on or before December 31, 2022." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000099/ibrx-20260930.htm)) |
| September 26, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06192108 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06192108)) |
| September 26, 2025 | [RAP-219 primary completion](https://sec-api.dev/pdufa/rap-219) | RAPP | Focal Onset Seizures | completed | "NCT06377930 (Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Rapport Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06377930)) |
| September 28, 2025 | [Tolebrutinib PDUFA date](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | delayed | "Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525077305/d942506dex991.htm)) |
| September 29, 2025 | [Anebulo Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/aneb/catalysts) | ANEB |  | completed | "Texas (September 29, 2025) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three and twelve months ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/ex99-1.htm)) |
| September 29, 2025 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA |  | completed, positive | "As noted in Item 7.01 above, Enanta announced positive topline data from its Phase 2b high-risk adults study of zelicapavir for the treatment of RSV on September 29, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312525221527/d16388d8k.htm)) |
| September 29, 2025 | [KOMET-017 trial start](https://sec-api.dev/pdufa/komet-017) | KURA | newly diagnosed NPM1-mutated or KMT2A-rearranged AML | completed | "On September 29, 2025, we and Kyowa Kirin announced the first patient dosed under the KOMET-017 protocol, which is comprised of two independent, global, randomized, double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive regimens in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| September 29, 2025 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502341)) |
| September 29, 2025 | [Cytisinicline primary completion](https://sec-api.dev/pdufa/cytisinicline) | QUIT | Smoking Cessation; Vaping Cessation | completed | "NCT06435221 (Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Achieve Life Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435221)) |
| September 30, 2025 | [Tonix Pharmaceuticals Holding Corp. NDA/BLA acceptance](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "During the nine months ended September 30, 2025, 13,666 warrants with an exercise price of $1,056 became exercisable, 5,758 warrants with an exercise price of $1,776 became exercisable upon FDA acceptance of our NDA filing, and 1 warrant with an exercise price of $364,800 expired." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1430306/000199937126024873/tnxp-10q_093026.htm)) |
| September 30, 2025 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, approved | "The decrease in research and development expenses for the nine months ended September 30, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our Phase 3 IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm)) |
| September 30, 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of September 30, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for RSV disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000075/mrna-20250930.htm)) |
| September 30, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of September 30, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312525277466/cue-20250930.htm)) |
| September 30, 2025 | [KAMADA LTD FDA approval](https://sec-api.dev/companies/kmda/catalysts) | KMDA |  | completed, approved | "Announced that the FDA has approved the supplement to the Company's existing Biologics License Application (BLA) for Kamada Plasma's collection center in Houston, TX." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567529/000121390025107836/ea026262101ex99-1_kamada.htm)) |
| September 30, 2025 | [MESOBLAST LTD label expansion decision](https://sec-api.dev/companies/meso/catalysts) | MESO |  | completed, approved | "RYONCIL, first & only FDA approved MSC product ✓On track for gross revenue >US$30 million this quarter ✓Onboarded >40 centers; 45 centers account for ~80% of U.S. pediatric BMTs ✓Initiating label expansion to adult aGvHD; 3-4x larger market v. pediatric ✓Inflammatory colitis trial IND filing Q1 CY26 Rexlemestrocel-L second generation platform ✓Enrollment for CLBP for expected to complete in Q1 CY26 ✓BLA filing for accelerated approval in end-stage CHF with LVADs Optimizing manufacturing & logistics in U.S. to support for future growth US$145m cash on hand at Sep 30, 2025 Management to host investor R&D day in Q1 CY26 Summary & Upcoming Milestones 22" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509925000101/exhibit992.htm)) |
| September 30, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | IgAN | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000049/biib-20250930.htm)) |
| September 30, 2025 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "•Within R&D, Novo Nordisk announced that the US FDA had approved an indication for Wegovy® for the treatment of MASH." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000035327825000005/caq32025.htm)) |
| September 30, 2025 | [Pasritamig trial start](https://sec-api.dev/pdufa/pasritamig) | ZYME |  | completed | "Revenue for the nine months ended September 30, 2025 included $25.0 million of non-refundable milestone revenue from J&J due to the achievement of research milestones in the Phase 3 clinical trial of pasritamig, $14.0 million of milestone revenue from GSK in relation to a clinical milestone under our 2016 platform technology transfer and license agreement, $3.1 million of milestone revenue from Daiichi Sankyo following the first patient dosed in a clinical trial related to the 2018 license agreement, a" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1937653/000193765325000077/zyme-20250930.htm)) |
| September 30, 2025 | [Amneal Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed, complete response letter | "For the three months ended September 30, 2025 and the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526dex991.htm)) |
| September 30, 2025 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended September 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm)) |
| September 30, 2025 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease | completed, complete response letter | "FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm)) |
| September 30, 2025 | [Zeposia (ozanimod hydrochloride) primary completion](https://sec-api.dev/pdufa/ozanimod) | BMY | Colitis, Ulcerative | completed | "NCT03915769 (To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03915769)) |
| September 30, 2025 | [INBRX-109 primary completion](https://sec-api.dev/pdufa/inbrx-109) | INBX | Conventional Chondrosarcoma | completed | "NCT04950075 (Study of INBRX-109 in Conventional Chondrosarcoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Inhibrx Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04950075)) |
| September 30, 2025 | [Bezuclastinib primary completion](https://sec-api.dev/pdufa/bezuclastinib) | COGT | Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer | completed | "NCT05208047 ((Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05208047)) |
| September 2025 | [Eb-101 surgical application of rdeb wounds primary completion](https://sec-api.dev/pdufa/eb-101-surgical-application-of-rdeb-wounds) | ABEO | Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB | delayed | "NCT05725018 (A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-30 (ESTIMATED); Lead Sponsor Abeona Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05725018)) |
| September 30, 2025 | [BRINSUPRI® (brensocatib) primary completion](https://sec-api.dev/pdufa/brensocatib) | INSM | Chronic Rhinosinusitis Without Nasal Polyps | completed | "NCT06013241 (A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06013241)) |
| September 30, 2025 | [Eltrekibart primary completion](https://sec-api.dev/pdufa/eltrekibart) | LLY | Hidradenitis Suppurativa | completed | "NCT06046729 (A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046729)) |
| September 30, 2025 | [AMX0035 primary completion](https://sec-api.dev/pdufa/amx0035) | AMLX | Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases | completed | "NCT06122662 (AMX0035 and Progressive Supranuclear Palsy): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Amylyx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122662)) |
| September 30, 2025 | [Primec primary completion](https://sec-api.dev/pdufa/primec) | NRSN | Alzheimer Disease | withdrawn | "NCT06185543 (A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor NeuroSense Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06185543)) |
| September 30, 2025 | [Respiratory syncytial virus prefusion f subunit vaccine primary completion](https://sec-api.dev/pdufa/respiratory-syncytial-virus-prefusion-f-subunit-vaccine) | PFE | Respiratory Syncytial Virus (RSV) | completed | "NCT06890416 (A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890416)) |
| September 30, 2025 | [Rhapsido® (remibrutinib) FDA approval](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | completed, approved | "Rhapsido \| remibrutinib \| 9/30/2025 \| To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatmentDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |

Other months: https://sec-api.dev/fda-calendar/2025-08 , https://sec-api.dev/fda-calendar/2025-10. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates September 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-09

```bibtex
@misc{secapidev_fda_calendar_2025_09_20261116,
  title        = {PDUFA dates September 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-09}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_09_20261116","title":"PDUFA dates September 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-09","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
